[go: up one dir, main page]

SE9702002D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE9702002D0
SE9702002D0 SE9702002A SE9702002A SE9702002D0 SE 9702002 D0 SE9702002 D0 SE 9702002D0 SE 9702002 A SE9702002 A SE 9702002A SE 9702002 A SE9702002 A SE 9702002A SE 9702002 D0 SE9702002 D0 SE 9702002D0
Authority
SE
Sweden
Prior art keywords
pct
sec
novel compounds
date
pub
Prior art date
Application number
SE9702002A
Other languages
Swedish (sv)
Inventor
Nicholas Kindon
Premji Meghani
Stephen Thom
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to SE9702002A priority Critical patent/SE9702002D0/en
Publication of SE9702002D0 publication Critical patent/SE9702002D0/en
Priority to ES98924708T priority patent/ES2156444T3/en
Priority to AT98924708T priority patent/ATE200489T1/en
Priority to JP50056799A priority patent/JP2002501528A/en
Priority to EP98924708A priority patent/EP0984963B1/en
Priority to DK98924708T priority patent/DK0984963T3/en
Priority to DE69800699T priority patent/DE69800699T2/en
Priority to PCT/SE1998/000940 priority patent/WO1998054180A1/en
Priority to AU76811/98A priority patent/AU7681198A/en
Priority to US09/091,187 priority patent/US6162808A/en
Priority to PT98924708T priority patent/PT984963E/en
Priority to GR20010401043T priority patent/GR3036195T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Liquid Crystal (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PCT No. PCT/SE98/00940 Sec. 371 Date Jun. 10, 1998 Sec. 102(e) Date Jun. 10, 1998 PCT Filed May 18, 1998 PCT Pub. No. WO98/54180 PCT Pub. Date Dec. 3, 1998The invention relates to new pharmaceutically active compounds which are P2-purinoceptor 7-transmembrane (TM) G-protein coupled receptor antagonists, compositions containing them and processes for their preparation.
SE9702002A 1997-05-28 1997-05-28 Novel compounds SE9702002D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9702002A SE9702002D0 (en) 1997-05-28 1997-05-28 Novel compounds
PT98924708T PT984963E (en) 1997-05-28 1998-05-18 NEW COMPOUNDS
EP98924708A EP0984963B1 (en) 1997-05-28 1998-05-18 Novel compounds
AT98924708T ATE200489T1 (en) 1997-05-28 1998-05-18 LINKS
JP50056799A JP2002501528A (en) 1997-05-28 1998-05-18 New compounds
ES98924708T ES2156444T3 (en) 1997-05-28 1998-05-18 NEW COMPOUNDS.
DK98924708T DK0984963T3 (en) 1997-05-28 1998-05-18 Hitherto unknown compounds
DE69800699T DE69800699T2 (en) 1997-05-28 1998-05-18 LINKS
PCT/SE1998/000940 WO1998054180A1 (en) 1997-05-28 1998-05-18 Novel compounds
AU76811/98A AU7681198A (en) 1997-05-28 1998-05-18 Novel compounds
US09/091,187 US6162808A (en) 1997-05-28 1998-05-18 Compounds
GR20010401043T GR3036195T3 (en) 1997-05-28 2001-07-10 Novel compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702002A SE9702002D0 (en) 1997-05-28 1997-05-28 Novel compounds

Publications (1)

Publication Number Publication Date
SE9702002D0 true SE9702002D0 (en) 1997-05-28

Family

ID=20407125

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9702002A SE9702002D0 (en) 1997-05-28 1997-05-28 Novel compounds

Country Status (12)

Country Link
US (1) US6162808A (en)
EP (1) EP0984963B1 (en)
JP (1) JP2002501528A (en)
AT (1) ATE200489T1 (en)
AU (1) AU7681198A (en)
DE (1) DE69800699T2 (en)
DK (1) DK0984963T3 (en)
ES (1) ES2156444T3 (en)
GR (1) GR3036195T3 (en)
PT (1) PT984963E (en)
SE (1) SE9702002D0 (en)
WO (1) WO1998054180A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69803883T2 (en) * 1997-11-21 2002-09-19 Astrazeneca Uk Ltd., London NEW CONNECTIONS THAT ARE ANTAGONISTS FOR P2-PURINO RECEPTOR 7-TRANSMEMBRANE (TM) G-PROTEIN COUPLED RECEPTORS
US7696168B2 (en) * 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
EP1278777B1 (en) 2000-04-21 2012-12-19 New England Medical Center G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
US20030151980A1 (en) * 2002-02-13 2003-08-14 Isador Farash Color referenced multi-time watch
AUPS160602A0 (en) 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
AU2005304963C1 (en) * 2004-11-04 2011-01-06 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
US7589213B2 (en) 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
AU2009246573B2 (en) 2008-05-15 2014-04-24 Allergan, Inc. Therapeutic substituted cyclopentanes
CN103159641A (en) * 2011-12-14 2013-06-19 天津泰普药品科技发展有限公司 Method for preparing intermediate 2-carboxylic acid-5-(2-methyl-benzoylamino)toluene for tolvaptan
EP2881390A1 (en) 2013-12-04 2015-06-10 Sanofi Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase
CN106045937B (en) * 2016-06-21 2019-04-16 杭州诺维和医药技术有限公司 A kind of synthetic method of { 2- [2- (2- amino -4- thiazolyl)-acetyl-amino] -4- thiazolyl }-acetic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2099868C (en) * 1991-01-31 2002-04-02 Thomas Richard Belliotti Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
IT1277373B1 (en) * 1995-07-28 1997-11-10 Consiglio Nazionale Ricerche USE OF AGONIST OR ANTAGONIST COMPOUNDS OF PURINE P2 RECEPTORS FOR THE PREVENTION OF GLUTAMATE CYTOTOXICITY

Also Published As

Publication number Publication date
PT984963E (en) 2001-07-31
DE69800699D1 (en) 2001-05-17
GR3036195T3 (en) 2001-10-31
EP0984963A1 (en) 2000-03-15
AU7681198A (en) 1998-12-30
US6162808A (en) 2000-12-19
ATE200489T1 (en) 2001-04-15
EP0984963B1 (en) 2001-04-11
ES2156444T3 (en) 2001-06-16
JP2002501528A (en) 2002-01-15
DK0984963T3 (en) 2001-06-05
WO1998054180A1 (en) 1998-12-03
DE69800699T2 (en) 2001-09-06

Similar Documents

Publication Publication Date Title
SE9702651D0 (en) Novel compounds
EP0903349A3 (en) CCR-3 receptor antagonists
BR0015963A (en) Muscarinic receptor antagonist urea compounds, pharmaceutical compositions comprising such compounds and method of preparing these compounds
TR200101155T2 (en) 4-Aroil Piperidine CCR-3 Receptor Antagonists III
DE69532162D1 (en) Cannabinoid receptor Antagonist
DE69932173D1 (en) ADENINE DERIVATIVES
ATE270663T1 (en) TRIZYCLIC 1-BENZYLPYRAZOLE-3- CARBOXYLIC ACID DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS
ES2158813A1 (en) Piperidine ccr-3 receptor antagonists
WO2003086303A3 (en) Farnesoid x-activated receptor agonists
SE9702002D0 (en) Novel compounds
MX9801890A (en) Novel human nk3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them.
SE9702794D0 (en) New compounds
NO963331L (en) 5-Heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
ES2172939T3 (en) NEW COMPOUNDS THAT ARE ANTAGONISTS OF RECEPTORS COUPLED TO PROTEIN G 7-TRANSMEMBRANE (TM) P2-PURINOCEPTORS.
NO944214D0 (en) Pharmaceuticals for rectal administration, containing alkylsulfonamides which are HT1 agonists
NO995685L (en) New glycosylated ginkgold derivatives, their use as medicaments and pharmaceutical compositions
NO20000654D0 (en) 1,3-dioxolo / 4,5-H // 2,3 / benzodiazepine derivatives as AMPA / KAINAT receptor inhibitors
ECSP972049A (en) LACTAMA DERIVATIVES
ECSP951512A (en) NEUROQUININE ANTAGONISTS